H1 secures $40M from CVS, proving SaaS startups can still attract investment

The landscape for SaaS startups has shifted dramatically in recent months, with many struggling to secure funding. However, H1, a seasoned healthcare data platform, has defied this trend by successfully securing a $40 million investment from CVS Health Ventures. Ariel Katz, the CEO and co-founder of H1, believes that not all software-as-a-service companies are facing the same challenges. He argues that while many workflow SaaS companies may struggle, those rooted in data provision, like H1, have a unique advantage. Katz stated, "If you’re a workflow SaaS company, you could vibe code that." He asserts that H1's core value lies in its extensive data on healthcare professionals, which he believes cannot be easily replicated by AI technologies. Katz expressed confidence in H1's position in the market, saying, "I don’t worry about Claude ever doing what we do," referencing Anthropic’s AI model. He sees potential collaboration opportunities with AI developers who may benefit from the wealth of physician data H1 collects worldwide. The backing from CVS Health Ventures reinforces the notion that H1 is not at risk of falling victim to the so-called "SaaSocalypse." Despite not actively seeking funding, H1's impressive financial turnaround, marked by profitability in cash flow and EBITDA last year, led to this substantial investment. Katz noted that the chance to partner with one of the largest healthcare organizations was simply too significant to pass up. While H1 is thriving, many traditional venture capitalists are currently fixated on the AI sector, often overlooking companies like H1. The startup was last valued at $750 million during a funding round in November 2021, just before market valuations began to decline. In response to the shifting financial climate, H1 has prioritized profitability and has expanded its reach through strategic acquisitions of smaller firms and complementary services.